Newsroom
Press
Releases
Press Releases
- 10.13.2021
Turning Point Therapeutics and EQRx Announce Clinical Collaboration to Evaluate Elzovantinib in Combination with Aumolertinib in Patients with EGFR Mutant MET-Amplified Advanced Non-Small Cell Lung Cancer
Under the terms of the agreement, Turning Point will sponsor and conduct a Phase 1b/2 clinical trial to evaluate the safety, tolerability and preliminary efficacy of the combination regimen and will assume all costs associated with the trial. EQRx will provide aumolertinib at no cost.
- 10.6.2021
EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs
Absci’s AI-powered discovery and development platform to further expand EQRx’s portfolio of innovative, affordable medicines
- 9.27.2021
EQRx Appoints Kathy Giusti to Board of Directors
EQRx announced the appointment of Kathy Giusti to the Company’s board of directors. Ms. Giusti is recognized as a pioneer in precision medicine and is the founder and chief mission officer of the Multiple Myeloma Research Foundation (MMRF).
- 9.17.2021
EQRx Announces Presentation of Phase 3 Data Demonstrating a Progression-Free Survival Benefit with Sugemalimab Consolidation Therapy in Patients with Stage III NSCLC at ESMO Congress 2021
Results from Stage III & Stage IV NSCLC studies suggest sugemalimab is a promising potential treatment option
- 9.13.2021
EQRx Announces Presentation of Updated Data from Pivotal Phase 3 Study of Anti-PD-L1 Antibody Sugemalimab in Combination with Chemotherapy as a First-Line Treatment for Stage IV NSCLC
Updated data from Phase 3 study of sugemalimab in Stage IV NSCLC presented at WCLC 2021